Format

Send to

Choose Destination
Nat Rev Drug Discov. 2008 Oct;7(10):841-53. doi: 10.1038/nrd2665.

Sirtuins--novel therapeutic targets to treat age-associated diseases.

Author information

1
Sirtris Pharmaceuticals, Cambridge, Massachusetts 02139, USA.

Erratum in

  • Nat Rev Drug Discov. 2009 Jun;8(6):516.

Abstract

Sirtuins post-translationally modulate the function of many cellular proteins that undergo reversible acetylation-deacetylation cycles, affecting physiological responses that have implications for treating diseases of ageing. Potent small-molecule modulators of sirtuins have shown efficacy in preclinical models of metabolic, neurodegenerative and inflammatory diseases, and so hold promise for drug discovery efforts in multiple therapeutic areas. Here, we discuss current knowledge and data that strengthens sirtuins as a druggable set of enzymes for the treatment of age-associated diseases, including activation of SIRT1 in type 2 diabetes.

PMID:
18827827
DOI:
10.1038/nrd2665
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center